cardiovascular diseases

News

Novo Nordisk joins molecular glue club with Neomorph deal

Big pharma’s interest in using protein degradation as a therapeutic strategy shows no sign of abating, as Novo Nordisk signs a wide-ranging deal with US biotech Neomorph t

News

Bayer takes novel deep vein thrombosis drug into phase 2

Bayer has started proof-of-concept testing of a potential new therapy for patients with deep vein thrombosis (DVT) that works in a different way to current drugs.

News

As Novartis backs off, Amgen said to be after Cytokinetics

Speculation about a takeover play for Cytokinetics isn’t going away, with Amgen the latest company to be linked to the company and its highly-anticipated cardiovascular dr

News

Bayer unit takes heart failure gene therapy into phase 2

Bayer’s AskBio gene therapy unit has started recruiting patients into a phase 2 trial of its AB-1002 candidate for congestive heart failure (CHF), buoyed by encouraging da

News

Cytokinetics rockets on positive heart drug trial

Shares in US biotech Cytokinetics have popped after a report that its aficamten drug improved symptoms in people with a rare and progressive form of heart disease.

News

BridgeBio rebounds on ATTR cardiomyopathy data

BridgeBio is getting ready to file for FDA approval of its acoramidis drug for transthyretin amyloidosis (ATTR) cardiomyopathy, armed with positive results in a phase 3 tr

Novo Nordisk joins molecular glue club with Neomorph deal

Bayer takes novel deep vein thrombosis drug into phase 2

As Novartis backs off, Amgen said to be after Cytokinetics

Bayer unit takes heart failure gene therapy into phase 2

Cytokinetics rockets on positive heart drug trial

BridgeBio rebounds on ATTR cardiomyopathy data

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

cardiovascular diseases

Editor's Picks